Asian Spectator


The Times

.

LANDMARK’s ‘Destination CENTRAL’ Opens an Inspiring New Chapter for the Festive Season in Hong Kong

Heightening the Global Momentum of Louis Vuitton’s Monumental Façade and Welcoming the Arrival of “Christmas at The Gloucester Hotel”HONG KONG SAR – Media OutReach News...

After Tripling 2019 Sales, Enterprise Results Platform Leader ...

REDWOOD CITY, California, Jan. 17, 2020 /PRNewswire-AsiaNet/ -- -- WorkBoard now the top choice for enterprise results alignmentWorkBoard( https://c212.net/c/link/?t=0&l=en&o=2694442...

McKay Brothers Adds Shanghai and Hong Kong to Asia Services

TOKYO and GENEVA, Nov. 20, 2019 /PRNewswire-AsiaNet/ -- -- New Asia offerings join McKay's Singapore-Tokyo lowest known latency serviceMcKay Brothers International (MBI) is now offering conn...

TCMA Launches The NEXT Chapter with 5 Engines to Accelerate Cement Industry Toward Net Zero 2050

Thai Cement Manufacturers Association (TCMA) has advanced its strategy, "The NEXT Chapter to Net Zero 2050," through five key implementation pillars - "5 Engines to Net Zero" - under the the...

Tianjin to host the third World Intelligence Congress to explo...

TIANJIN, China, May 16, 2019 /Xinhua-AsiaNet/-- The third World Intelligence Congress (WIC) will be held in the Meijiang Convention and Exhibition Center in north China's Tianjin Municipalit...

Allianz Commercial: AI and cloud computing drive global construction boom for data centers

Global spending on data centers is expected to reach several trillion US dollars by 2030 with the US and China as main drivers of growth. The surging demand for data center...

MHI Thermal Systems' Plug-in Hybrid Transport Refrigeration Units Win 2019 Agency for Natural Resources and Energy Commissioner's Award

TOKYO, Jan 29, 2020 - (JCN Newswire) - Plug-in hybrid transport refrigeration units made by Mitsubishi Heavy Industries Thermal Systems, Ltd. (MHI Thermal Systems), a part of Mitsubishi Hea...

Ugreen Launches Nexode 100W Charger with New GaN Technology.

HONG KONG, Apr. 2, 2022 /PRNewswire-AsiaNet/-- Ugreen(https://www.ugreen.com/), a global leader in charging accessories, is announcing the release of the Nexode 100W charger. The Nexode 100W...

WPI-MANA Devises New Way to Observe Heat Flows at Nanoscale

TSUKUBA, Japan, Nov. 12, 2019 /Kyodo JBN-AsiaNet/ -- A team at the International Center for Materials Nanoarchitectonics (WPI-MANA), a unit of the National Institute for Materials Science (N...

Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China

Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China

TOKYO, Feb 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in China.

Based on this agreement, Eisai will acquire exclusive development and marketing rights for dotinurad in China from FUJI YAKUHIN. FUJI YAKUHIN will retain responsibility for manufacturing the formulation of dotinurad, and supply to Eisai. Eisai will be responsible for a New Drug Application for dotinurad in China and pay FUJI YAKUHIN upfront payment, development milestone and sales milestone.

Hyperuricemia is the second most common metabolic disease after diabetes mellitus in China. In addition, hyperuricemia is known to be associated with various diseases in the urinary system, endocrine system, metabolic system, cardio-cerebrovascular system etc., including gout.

Furthermore, it is estimated that currently in China, the number of patients with hyperuricemia is approximately 190 million and the number of patients with gout is approximately 16 million.(1) It is expected that the number of patients will further increase in the near future due to changes in lifestyle and dietary preferences in accordance with socio-economic development in China.

Dotinurad is a new therapeutic agent for gout and hyperuricemia discovered by FUJI YAKUHIN. Dotinurad suppresses uric acid reabsorption and lowers blood uric acid levels, by selectively inhibiting the urate transporter (URAT1) related to reabsorption of uric acid in the kidney.

Under this agreement, Eisai will proceed with the development of dotinurad in China. Following commercialization, Eisai will aim to contribute to patients with hyperuricemia that are unmet medical needs by utilizing the knowledge and networks that Eisai has cultivated through its China business. FUJI YAKUHIN anticipates maximizing the value of dotinurad in China by leveraging Eisai's business base as the first step in the global expansion of dotinurad. Through the development and commercialization of dotinurad, Eisai and FUJI YAKUHIN will provide new treatment options for hyperuricemia and gout in China and contribute to improving the quality of life of patients.

About Eisai Co., Ltd.

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For further information on Eisai Co., Ltd., please visit https://www.eisai.com.

About FUJI YAKUHIN CO., LTD.

FUJI YAKUHIN CO., LTD. is a complex pharmaceutical company with an integrated manufacturing and sales system consisting of ethical drug sales, placement drug sales, drugstore business, and the pharmaceutical manufacturing business that supports them. Regarding ethical drugs, FUJI YAKUHIN has created two drugs with different mechanisms of action, topiroxostat and dotinurad, for gout and hyperuricemia.

For further information on FUJI YAKUHIN CO., LTD., please visit https://www.fujiyakuhin.co.jp/ (Japanese only)

About dotinurad

URAT1 and has a small effect on other transporters, so it reduces serum uric acid levels at lower doses. Dotinurad is expected to have a low risk of side effects and drug interaction.In Japan, on January 23, 2020, FUJI YAKUHIN CO., LTD. obtained manufacturing and marketing approval for dotinurad.

References:(1) For the estimated data regarding the number of patients with hyperuricemia as well as the number of patients with gout:- Dataofmorbidityprevalencerate-RuiLiuetal., PrevalenceofHyperuricemiaandGoutinMainlandChinafrom2000to2014: A Systematic Review and Meta-Analysis, BioMed Research International, Volume 2015, Article ID 762820- Estimated data calculated from United Nations World Population Estimates - World Population Prospects, URL: http://www.un.org/en/development/desa/population/

Contact:Eisai Co., Ltd.
Public Relations Department 
TEL: +81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalzlibraryzlibraryuk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet girişStreamEastStreamEastjojobetcialis 20 mg fiyat